Skip to main content
. 2017 Jul 17;127(8):3052–3064. doi: 10.1172/JCI89756

Figure 8. Ability of CLL cells to produce IL-10 is impaired with BTK inhibitor treatment.

Figure 8

PBMCs from CLL patients were collected before and during treatment with ibrutinib (A–C) and acalabrutinib (D). Cells were stimulated in vitro with CpG and PMA/ionomycin for 5 hours (B10 conditions) or with CpG/CD40L for 48 hours, with PMA/ionomycin added for the last 5 hours (B10Pro conditions). IL-10 production was detected by intracellular cytokine staining. All events were gated on CLL cells (CD19+CD5+CD3–). (A) Representative flow cytometry plots of IL-10 expression in CLL cells under B10 conditions (top) and B10Pro conditions (bottom). (B) CLL samples were collected at baseline and at the beginning of cycles 3 and 6 (8 and 20 weeks, respectively) after starting ibrutinib treatment. Graphs show the percentages of IL-10 producing CLL cells after in vitro incubation under B10 conditions (left; n = 13) and B10Pro conditions (right; n = 18). (C) PBMCs were collected from CLL patients at baseline and at the beginning of cycles 3 and 6 (8 and 20 weeks, respectively) after starting acalabrutinib treatment. Graphs show the percentages of IL-10–producing CLL cells after in vitro incubation under B10 conditions (left; n = 10) and B10Pro conditions (right; n = 12). Differences were assessed using linear mixed-effects models.